Trials / Completed
CompletedNCT02188173
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dexamethasone 700 ㎍ intravitreal implant | Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices. |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2014-07-11
- Last updated
- 2016-06-01
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02188173. Inclusion in this directory is not an endorsement.